Goldman Sachs Maintains Sell on Baxter Intl, Lowers Price Target to $60
Goldman Sachs analyst Amit Hazan maintains Baxter Intl (NYSE:BAX) with a Sell and lowers the price target from $70 to $60.
Raymond James Maintains Outperform on Baxter Intl, Lowers Price Target to $66
Raymond James analyst Jayson Bedford maintains Baxter Intl (NYSE:BAX) with a Outperform and lowers the price target from $85 to $66.
Morgan Stanley Maintains Overweight on Baxter Intl, Lowers Price Target to $72
Morgan Stanley analyst Drew Ranieri maintains Baxter Intl (NYSE:BAX) with a Overweight and lowers the price target from $86 to $72.
This Healthcare Stock Tumbled 43%; Here Are 88 Biggest Movers From Yesterday
Gainers
Athersys, Inc. (NASDAQ: ATHX) climbed 71.1% to close at $0.3250 on Thursday after gaining 10% on Wednesday. Athersys is expected to release its Q2 financial results on Thursday, August 11, 2022.
Where Baxter Intl Stands With Analysts
Baxter Intl (NYSE:BAX) has observed the following analyst ratings within the last quarter: